Strides Pharma achieves strong ESG performance, top 10% in global assessment

Strides Pharma Science Limited has released its Sustainability Report for FY25, detailing strong ESG performance and strategic initiatives. The company achieved a remarkable S&P Global Corporate Sustainability Assessment (CSA) score of 75 in its first-time participation, placing it among the top 10% across all industries worldwide.

Key highlights include 100% employee training in the Code of Conduct, 93.1% average board meeting attendance, and 62.5% independent directors. In healthcare access, Strides supplied 2.4 bn doses of AL for Malaria since 2013, reaching patients in over 60 countries, and 800 bn doses of TLD for HIV since 2020 to more than 26 countries. The company's clean energy share for FY25 stands at 42.65%, contributing to a total energy consumption of 46,009.77 MWh.

Strides also reported zero incidents of non-compliance concerning health and safety impacts of products and services, as well as zero information security breaches. These achievements underscore the company's commitment to responsible growth and long-term value creation for stakeholders.